Despite extensive efforts by global pharmaceutical companies to develop FGF21 analogues, several clinical trials failed to produce positive outcomes for the treatment of type 2 diabetes and its related metabolic disorders19,28,39. This evidence concerns the gene FGF21 and type 2 diabetes mellitus.